12 September 2024 - PHARMAC is asking for feedback on two changes for people with attention deficit hyperactivity disorder - a new medicine, and changes to the renewal criteria.

PHARMAC is proposing to fund lisdexamphetamine mesylate (Vyvanse) for the treatment of attention deficit hyperactivity disorder, and to remove the renewal criteria for stimulant medicines, used in the treatment of attention deficit hyperactivity disorder and narcolepsy.

Read PHARMAC consultation